top of page

When the Contract Becomes the Weapon: PBM Power and Plan Oversight

11 hours ago
5 min read

A congressional report describes the contractual tools one PBM allegedly used to control a market. The same concentration that worries antitrust regulators should worry plan fiduciaries.


In January 2026, the U.S. House Judiciary Committee released an interim staff report titled When CVS Writes the Rules, describing how, in the committee's account, CVS used network contracts, audits, and cease-and-desist letters to limit independent pharmacies' use of certain hub services and digital platforms. The report asserts that CVS leveraged its provider manual and market position, covering roughly 30% of the insured population through CVS Caremark's network, to discourage competition. The findings are the committee's allegations; CVS has contested aspects of the committee's account.


The account has since drawn a regulatory response. On July 14, 2026, the Federal Trade Commission announced a proposed consent order with Caremark that, among other terms, prohibits the PBM from unfairly interfering with pharmacies' ability to work with hub service providers, with the prohibition backed by a monitor. The FTC cited the committee's report in announcing the settlement, which was still proposed, not final, as of October 2026. Caremark admitted no wrongdoing.


Set aside the antitrust debate for a moment. For self-funded plan fiduciaries, the report is useful for a different reason: it is a detailed, public illustration of how contractual instruments, the manual, the audit right, the cease-and-desist letter, become instruments of control when one party holds concentrated market power. The same tools, and the same concentration, sit inside the arrangements that administer your plan.


~30%

Of the insured population in CVS Caremark's network, per the committee report

3

Contractual instruments the report describes: network contracts, audits, cease-and-desist letters

100%

Of your claims an independent reviewer examines, outside that power


The Contract as an Instrument of Power

A contract is usually thought of as a mutual agreement between parties of roughly comparable footing. The House Judiciary report describes something different: a setting where one party's market concentration lets it use ordinary contractual mechanisms, manual provisions, audit rights, formal demand letters, to shape the behavior of much smaller counterparties. When market power is that lopsided, the contract is less a negotiated bargain than a lever.


When one party holds concentrated market power, ordinary contractual tools, manuals, the audit right, the demand letter, stop being a bargain and start being a lever.

Self-funded plan sponsors should recognize the dynamic, because they sit on the smaller-counterparty side of a similarly concentrated market. The carriers, TPAs, and PBMs that administer self-funded plans operate at enormous scale relative to most individual employers. The same instruments the report describes, manual terms, audit provisions, and data-access limitations, appear in ASO and PBM agreements, and the same information and leverage imbalance can shape what the plan can see and do.


Why Concentration Is a Fiduciary Concern, Not Just an Antitrust One

Market concentration is usually framed as a competition problem. For a fiduciary, it is also an oversight problem. When the entity administering your plan holds concentrated power and controls the contract, the data, and the reporting, the plan's practical ability to verify what is happening to its assets is constrained, regardless of what the contract nominally permits. ERISA's duty to monitor service providers does not bend to market structure; the duty is the same whether your administrator is a small vendor or a market-dominant one. But discharging it is harder where power is concentrated, exactly where it matters most.


This connects directly to the litigation pattern seen elsewhere, where carriers controlling both plan assets and claims data became the recurring condition behind alleged misconduct. See Inside a Litigated Claims Review: What One Unsealed Report Reveals (Comau v. BCBSM).


How a Plan Restores Its Own Leverage

  • Read the manual and audit provisions as power, not boilerplate. The provisions a dominant administrator relies on are the provisions worth scrutinizing before you sign.

  • Secure unrestricted data-access rights. Concentration matters less when your right to your own claim-level data is explicit and not subject to the administrator's discretion.

  • Bring in an independent party. Independent claims review operates outside the administrator's power structure, giving the plan a source of truth the dominant party does not control.

  • Document everything. Where leverage is imbalanced, a contemporaneous record of what you asked for, received, and did is the fiduciary's most reliable protection.


Get a Source of Truth the Dominant Party Doesn't Control


ClaimInformatics reviews 100% of your claims independently, outside the carrier, TPA, and PBM power structure, so concentrated market power does not become concentrated control over what your plan is allowed to know.


Schedule a confidential assessment: claiminformatics.com/contact or send an email to hello@claiminformatics.com for immediate follow-up.


FAQs Block

What is the House Judiciary report about?

Released in January 2026 and titled “When CVS Writes the Rules,” the interim staff report describes, in the committee's account, CVS using network contracts, audits, and cease-and-desist letters to limit independent pharmacies' use of certain hub and digital-pharmacy services. The findings are the committee's allegations, and CVS has contested aspects of the account. In July 2026, the FTC announced a proposed consent order with Caremark that bars unfair interference with pharmacies' work with hub service providers and cites the committee's report.


Why should plan fiduciaries care about a PBM antitrust report?

Because it illustrates how ordinary contractual tools become instruments of control when one party holds concentrated market power, the same dynamic self-funded plans face with large carriers, TPAs, and PBMs. The report is a public, detailed map of a power imbalance that also shapes plan oversight.


Is concentrated market power a fiduciary issue?

It is. ERISA's duty to monitor service providers does not change with market structure, but it is harder to discharge when the administrator controls the contract, the data, and the reporting. Concentration makes independent verification more necessary, not less.


What contractual provisions deserve the most scrutiny?

Provider-manual terms, audit rights, data-access limitations, and compensation language, the same categories of instrument the report highlights. In a concentrated market, these provisions function as leverage and should be read accordingly before signing.


How does a plan offset an administrator's market power?

By securing explicit, unrestricted rights to its own claim-level data, bringing in an independent reviewer who operates outside the administrator's structure, and documenting every request and response. Independent verification gives the plan a source of truth the dominant party does not control.


The Bottom Line

The House Judiciary report on CVS is, for plan fiduciaries, less about one company than about what happens when market power is concentrated: contracts stop being bargains and become levers. Self-funded plans sit on the smaller side of exactly that imbalance with their carriers, TPAs, and PBMs. The duty to monitor doesn't bend to market structure, but meeting it requires a source of truth the dominant party doesn't control, which is precisely what independent verification provides.


When you read your administrator's manual and audit terms, do they look like a mutual bargain, or like leverage? Share your read in the comments.


Related Resources from ClaimInformatics


Verified Sources

Source

Reference

Link

U.S. House Judiciary Committee

When CVS Writes the Rules (interim staff report on CVS cease-and-desist practices, Jan. 21, 2026)

judiciary.house.gov

Federal Trade Commission

FTC Secures Major Settlement with Caremark (proposed consent order barring interference with hub service providers, Jul. 14, 2026)

ftc.gov

Cornell LII

ERISA §404 fiduciary duties (29 U.S.C. §1104)

law.cornell.edu

Cornell LII

ERISA §406 prohibited transactions (29 U.S.C. §1106)

law.cornell.edu

U.S. Congress

Consolidated Appropriations Act, 2021 (H.R.133)

congress.gov H.R.133

U.S. DOL / EBSA

Employee Benefits Security Administration, fiduciary responsibilities

dol.gov/agencies/ebsa



This content is provided for fiduciary decision-making and educational purposes and does not constitute legal advice. Characterizations of the House Judiciary Committee report reflect that committee's allegations; the subject company has contested aspects of the account, and no findings of liability are asserted here.

Comments


bottom of page